Telo Genomics Revenue vs. Number Of Shares Shorted

TELO Stock  CAD 0.12  0.01  9.09%   
Based on Telo Genomics' profitability indicators, Telo Genomics Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Telo Genomics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2019-03-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
0.0
 
Covid
At this time, Telo Genomics' Graham Number is fairly stable compared to the past year. Shareholders Equity Per Share is likely to climb to 0.13 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.12).
For Telo Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telo Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telo Genomics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telo Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telo Genomics Corp over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Telo Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telo Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telo Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Telo Genomics Corp Number Of Shares Shorted vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth.
Telo Genomics Corp is currently under evaluation in revenue category among its peers. It is currently regarded as top stock in number of shares shorted category among its peers . At this time, Telo Genomics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.

Telo Revenue vs. Competition

Telo Genomics Corp is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 2.14 Million. Telo Genomics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.

Telo Number Of Shares Shorted vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Telo Genomics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
null
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Telo Genomics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
2.46 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Telo Number Of Shares Shorted Comparison

Telo Genomics is currently under evaluation in number of shares shorted category among its peers.

Telo Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Telo Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telo Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Telo Genomics' change in net profit over the period of time. It can combine multiple indicators of Telo Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income37.8 K64.2 K
Operating Income-2.5 M-2.7 M
Income Before Tax-2.5 M-2.7 M
Total Other Income Expense Net-6 K-6.3 K
Net Loss-2.5 M-2.7 M
Income Tax Expense-4.7 K-4.4 K
Net Loss-3.2 M-3.4 M
Net Loss-2.4 M-2.5 M
Change To Netincome136.3 K129.5 K
Net Loss(0.04)(0.02)
Income Quality 0.91  1.12 

Telo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Telo Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telo Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telo Genomics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Telo Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Use Investing Themes to Complement your Telo Genomics position

In addition to having Telo Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Books Thematic Idea Now

Books
Books Theme
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.